HISTOPATHOLOGY REPORTING GUIDE:
Malignant ovarian surface epithelial/stromal tumours

Last name............................................Date of birth..................
Forename.................................
Patient identifiers.................................Date of request ..............

Clinical History.................................................................
Clinical presentation ..........................................................
Hormonal status.....................................Medical history .............Hormonal therapy .........
Family history..........................................................
Previous biopsies or cytological samples ..................................
Tumour markers ..........................................................
Previous chemotherapy ........................................

Details of surgical specimen
Left □ Right □
Biopsy □ partial oophorectomy □ oophorectomy □ salpingo-oophorectomy □
Hysterectomy with salpingo-oophorectomy □ pelvic exenteration □
Accompanying specimens
peritoneal biopsy □ omentum □ appendix □ peritoneal washings/ascitic fluid □
lymph nodes (specify) □ ..................................other (specify) □

Gross description
Tumour
Intact tumour □ fragmented tumour □ ovarian capsule: intact □ breached □
Macroscopic surface involvement: yes □ no □
Tumour size in 3 dimensions ....x....x....mm.
Tumour colour .............................................. tumour consistency....................
Presence of cysts □ presence of papillary areas □ presence of solid areas □
Tumour necrosis □ tumour haemorrhage □
Accompanying specimens
Biopsies (dimensions) ..................................mm
Omentum (dimensions) ..................................mm (description)..........................
Appendix (dimensions) ..................................mm (description)..........................
Lymph nodes (dimensions) ..................................mm
Others specimens ................................................................................

Relationship to adjacent or attached structures..........................................................
## Data to be included in the final pathology report - I

**Histological type (World Health Organization (WHO) 2002 classification (15)**

### Serous tumours
- **Malignant**
  - Adenocarcinoma
  - Surface papillary adenocarcinoma
  - Adenocarcinofibroma
- **Borderline tumours**
  - Papillary cystic tumour
  - Surface papillary tumour
  - Adenofibroma, cystoadenofibroma
- **Benign**
  - Cystadenoma
  - Papillary cystadenoma
  - Surface papilloma
  - Adenofibroma and cystadenofibroma

### Mucinous tumours
- **Malignant**
  - Adenocarcinoma
  - Adenocarcinofibroma
- **Borderline tumours**
  - Intestinal type
  - Endocervical-like
- **Benign**
  - Cystadenoma
  - Adenofibroma and cystadenofibroma

### Endometrioid tumours
- **Malignant**
  - Adenocarcinoma
  - Adenocarcinofibroma
  - Malignant Mullerian mixed tumour
  - Adenosarcoma
  - Endometrioid stromal sarcoma (low grade)
  - Undifferentiated ovarian sarcoma
- **Borderline tumours**
  - Cystic tumour
  - Adenofibroma and cystadenofibroma
- **Benign**
  - Cystadenoma
  - Adenofibroma and cystadenofibroma

### Clear cell tumours
- **Malignant**
  - Adenocarcinoma
  - Adenocarcinofibroma
- **Borderline tumours**
  - Cystic tumour
  - Adenofibroma, cystoadenofibroma
- **Benign**
  - Cystadenoma
  - Adenofibroma and cystadenofibroma

### Transitional cells tumours
- **Malignant**
  - Transitional cell carcinoma (non-Brenner type)
  - Malignant Brenner tumour
- **Borderline tumours**
  - Borderline Brenner tumour
- **Benign**
  - Brenner tumour

### Squamous cell tumours
- **Squamous cell carcinoma**
- **Epidermoid cyst**

### Mixed epithelial tumours (specify components)
- **Malignant**
- **Borderline**
- **Benign**

### Undifferentiated and unclassified tumours
- Undifferentiated carcinoma
- Adenocarcinoma, not otherwise specified
# Data to be included in the final pathology report - II

**Histological grade:**
- Serous carcinoma: Low-grade [ ] High-grade [ ]
- Carcinosarcoma, clear cell carcinoma, undifferentiated carcinoma: High-grade/grade3 [ ]
- Endometrial and mucinous adenocarcinoma: grade 1 [ ] grade 2 [ ] grade 3 [ ]

# Data to be included in the final pathology report - III

**Laterality:** right [ ] left [ ]

**Microscopic evidence of lymphovascular invasion:** Yes [ ] No [ ] Not assessable [ ]

**Involvement of ovarian capsule:** Yes [ ] No [ ] Not assessable [ ]

**Malignant cells in peritoneal/ascitic fluid:** Yes [ ] No [ ] Not assessable [ ]

**Peritoneal deposits:** Present [ ] Absent [ ] Not assessable [ ]

**Tubal involvement:** No [ ] Macroscopic [ ]

**Uterine serosal involvement:** No [ ] Macroscopic [ ] Microscopic [ ]

**Omental involvement:** No [ ] Macroscopic [ ] Microscopic [ ]

**Peritoneal metastasis:** No [ ] Yes [ ]

**Lymph node involvement:** No [ ] Yes [ ]

**Other findings (specify):**

**Distant metastasis:** Present [ ] Absent [ ] Not known [ ]

# Data to be included in the final pathology report - IV

**Pre-existing borderline tumour:** Present [ ] Absent [ ]

**Endometriosis:** Present [ ] Absent [ ]

**Post chemotherapy changes:** Present [ ] Absent [ ]

**Immunohistochemistry (optional; specify):**

**Other ancillary studies (optional; specify):**
**Data to be included in the final pathology report -**

**Pathologic ovarian staging form:** extent of disease through completion of definitive surgery (22)

<table>
<thead>
<tr>
<th>Primary tumour (T)</th>
<th>TNM category</th>
<th>FIGO STAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary tumour cannot be assessed:</td>
<td>TX</td>
<td></td>
</tr>
<tr>
<td>No evidence of primary tumour:</td>
<td>T0</td>
<td></td>
</tr>
<tr>
<td>Tumour limited to ovaries (one or both):</td>
<td>T1</td>
<td>I</td>
</tr>
<tr>
<td>Tumour is limited to one ovary, capsule intact, no tumour on ovarian surface, no cancer cells in the abdominal fluid:</td>
<td>T1a</td>
<td>IA</td>
</tr>
<tr>
<td>Tumours limited to both ovaries, capsules intact, no cancer cells in the abdominal fluid:</td>
<td>T1b</td>
<td>IB</td>
</tr>
<tr>
<td>Tumour limited to one or both ovaries with any of the following: capsule ruptured, tumour on ovarian surface, cancer cells in the abdominal fluid:</td>
<td>T1c</td>
<td>IC</td>
</tr>
<tr>
<td>The tumour involves one or both ovaries with pelvic extension</td>
<td>T2</td>
<td>II</td>
</tr>
<tr>
<td>Extension and/or implants on uterus and/or tubes. No cancer cells are found in the abdominal fluid:</td>
<td>T2a</td>
<td>IIA</td>
</tr>
<tr>
<td>Extension and/or implants on other pelvic tissue. No cancer cells in the abdominal fluid:</td>
<td>T2b</td>
<td>IIB</td>
</tr>
<tr>
<td>Pelvic extension and/or implants with cancer cells in the abdominal fluid:</td>
<td>T2c</td>
<td>IIC</td>
</tr>
<tr>
<td>Tumour involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis</td>
<td>T3</td>
<td>III</td>
</tr>
<tr>
<td>Microscopic peritoneal metastasis beyond the pelvis, no macroscopic tumour</td>
<td>T3a</td>
<td>IIIA</td>
</tr>
<tr>
<td>Macroscopic peritoneal metastasis beyond pelvis 2 cm or less:</td>
<td>T3b</td>
<td>IIIB</td>
</tr>
<tr>
<td>Peritoneal metastasis beyond pelvis more than 2 cm and/or regional lymph nodes metastasis:</td>
<td>T3c</td>
<td>IIIC</td>
</tr>
</tbody>
</table>

**Regional lymph nodes (T)**

| Regional lymph nodes cannot be assessed: | NX |  |
| No regional lymph nodes metastasis: | N0 |  |
| Regional lymph nodes metastasis: | N1 | IIIC |

**Distant metastasis (M)**

| Distant metastasis (excludes peritoneal metastasis) | M0 |  |
| N0 (No pathological M0; use the clinical M to complete stage group) | M0 |  |
| Distant metastasis | M1 | IV |